Interactions between Sclerostin and Glycosaminoglycans

Area of Science:

• Biochemistry
• Molecular Biology
• Skeletal Biology

Background:

• Sclerostin (SOST) is a critical negative regulator of Wnt signaling in bone formation.
• Glycosaminoglycans (GAGs) play diverse roles in biological processes, including skeletal development.
• Understanding GAG-protein interactions is crucial for elucidating molecular mechanisms in bone biology.

Purpose of the Study:

• To investigate the binding kinetics and structural characteristics of interactions between sclerostin and various glycosaminoglycans.
• To determine the effect of physiological conditions on sclerostin-GAG interactions.
• To identify the minimal heparin oligosaccharide length required for effective sclerostin binding.

Main Methods:

• Surface Plasmon Resonance (SPR) for real-time, label-free analysis of molecular interactions.
• Liquid Chromatography-Mass Spectrometry (LC-MS) for structural characterization of bound GAGs.
• Biophysical characterization of recombinant human (rhSOST) and mouse (rmSOST) sclerostin interactions with GAGs.

Main Results:

• Both rhSOST and rmSOST exhibit high-affinity binding to heparin (K_D ~36 nM and ~77 nM, respectively).
• An octadecasaccharide (18mer) was identified as the shortest heparin oligosaccharide that competes with full-length heparin for SOST binding.
• Sclerostin also interacts with other highly sulfated GAGs, including dermatan sulfate and chondroitin sulfate E.

Conclusions:

• Sclerostin possesses high-affinity binding capabilities for heparin and other specific sulfated GAGs.
• These findings provide insights into the molecular interactions of sclerostin with GAGs, potentially influencing Wnt signaling in bone.
• The study characterizes the biophysical properties of sclerostin-GAG interactions under varying physiological conditions.